Virtu Financial LLC Makes New $37,000 Investment in Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Virtu Financial LLC acquired a new position in shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 13,035 shares of the company’s stock, valued at approximately $37,000.

Other hedge funds also recently modified their holdings of the company. Marshall Wace LLP acquired a new stake in Poseida Therapeutics in the second quarter worth $31,000. Principal Financial Group Inc. bought a new position in shares of Poseida Therapeutics during the 2nd quarter worth about $35,000. Rothschild Investment LLC acquired a new stake in shares of Poseida Therapeutics in the 2nd quarter valued at about $35,000. Intech Investment Management LLC bought a new stake in Poseida Therapeutics in the 3rd quarter valued at about $46,000. Finally, Mackenzie Financial Corp bought a new position in Poseida Therapeutics in the second quarter worth approximately $51,000. Institutional investors own 46.87% of the company’s stock.

Poseida Therapeutics Trading Up 0.4 %

NASDAQ PSTX opened at $9.45 on Friday. The company has a current ratio of 3.20, a quick ratio of 3.20 and a debt-to-equity ratio of 0.68. The business has a fifty day simple moving average of $5.26 and a 200 day simple moving average of $3.76. Poseida Therapeutics, Inc. has a 12 month low of $1.87 and a 12 month high of $9.58. The firm has a market capitalization of $923.96 million, a P/E ratio of -15.00 and a beta of 1.64.

Analysts Set New Price Targets

Several equities research analysts have recently commented on PSTX shares. Piper Sandler downgraded Poseida Therapeutics from an “overweight” rating to a “neutral” rating and set a $10.00 price objective for the company. in a report on Monday, December 2nd. William Blair restated a “market perform” rating on shares of Poseida Therapeutics in a research note on Tuesday, November 26th. BTIG Research reaffirmed a “neutral” rating on shares of Poseida Therapeutics in a research note on Tuesday, November 26th. Cantor Fitzgerald downgraded shares of Poseida Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 26th. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $9.00 price target (down previously from $20.00) on shares of Poseida Therapeutics in a research report on Tuesday, November 26th. Five research analysts have rated the stock with a hold rating, According to MarketBeat, Poseida Therapeutics presently has an average rating of “Hold” and a consensus price target of $9.50.

Insider Transactions at Poseida Therapeutics

In other Poseida Therapeutics news, Chairman Mark J. Gergen sold 30,000 shares of Poseida Therapeutics stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $9.46, for a total transaction of $283,800.00. Following the transaction, the chairman now owns 651,291 shares of the company’s stock, valued at $6,161,212.86. This trade represents a 4.40 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 2.90% of the company’s stock.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.